NCT05794659 - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 15, 2025

Study Completion Date

November 15, 2027

Conditions

Advanced Ovarian Cancer

Interventions

BIOLOGICAL

AST-201

i.d. (3-week interval, 3 cycles in total)

DRUG

Paclitaxel

3-week interval, 6 cycles in total

DRUG

Carboplatin

3-week interval, 6 cycles in total

DRUG

Placebo

i.d. (3-week interval, 3 cycles in total)

DRUG

rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)

i.d. (3-week interval, 3 cycles in total)

Trial Locations (1)

University of Washington, Seattle